Ipamorelin Compound Reference
Published · Last updated · Publisher: ENOS Labs USA
What is Ipamorelin?
Ipamorelin is a synthetic pentapeptide that activates the ghrelin receptor and was described in 1998 as the first selective growth hormone secretagogue, meaning it raised growth hormone in animal models without the cortisol and prolactin rises seen with earlier compounds. Human data are limited to early pharmacology studies. It is not FDA approved.
- Synonyms
- NNC 26-0161
- Classification
- Synthetic pentapeptide growth hormone secretagogue (ghrelin receptor agonist)
What is Ipamorelin?
Ipamorelin was developed by Novo Nordisk as part of the growth hormone releasing peptide family.
Research context
Studies examined growth hormone release selectivity in animals, bone growth in rats and pharmacokinetics in volunteers.
Mechanisms being investigated
- Agonism at the growth hormone secretagogue receptor (GHS-R1a), the ghrelin receptor.
Research status
Approval status: Not approved for human use. Highest evidence tier in the cited literature: preclinical and early human.
Not approved by the FDA for any use. Published human data are limited to early pharmacology studies.
Established findings
- Selective GHS-R1a agonism described in animal pharmacology.
- Human pharmacokinetic modeling was published in 1999.
Preliminary or experimental findings
- Effects outside acute growth hormone release.
- Long term safety.
Chemical reference information
| Molecular formula | C38H49N9O5 |
|---|---|
| Molecular weight | 711.9 g/mol |
| CAS number | 170851-70-4 |
| PubChem CID | 9831659 |
Values taken from the PubChem record.
Testing considerations
- Contains non natural residues (Aib, D-2-Nal, D-Phe); stereochemistry is not resolved by intact mass alone.
General methods are explained in purity versus identity testing.
What is still unknown
- Human outcomes beyond pharmacology studies.
Related resources
ENOS catalog listing: Ipamorelin 10MG, CJC-1295 + IPA Blend 10MG
Research use limitations
This page summarizes published research and regulatory status. It is not medical advice and does not describe any use in people. Material supplied by ENOS Labs USA is for in-vitro laboratory research only and is not a drug product, even where a related drug has been approved.
To continue, see recovery and performance research, how to read a certificate of analysis, why purity and identity are separate tests, the compound directory and the peptide testing glossary.
References
Each source below was opened and checked against its PubMed, ClinicalTrials.gov or PubChem record. Links open in a new tab.
- Ipamorelin, the first selective growth hormone secretagogue (PMID 9849822)European Journal of Endocrinology, 1998 · PubMed
- Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers (PMID 10496658)Pharmaceutical Research, 1999 · PubMed
- Ipamorelin compound record (PubChem CID 9831659)PubChem · NIH National Library of Medicine
These products are sold strictly for in-vitro laboratory research and are not intended for human consumption, diagnosis, treatment, or any therapeutic use. Purchaser must be 18 years of age or older and confirms they are a qualified researcher.